Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Tumor necrosis factor gen… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy

Artikel i vetenskaplig tidskrift
Författare Lisa Ternström
Anders Jeppsson
Anne Ricksten
Folke Nilsson
Publicerad i J Heart Lung Transplant
Volym 24
Nummer/häfte 4
Sidor 433-8
ISSN 1053-2498 (Print)
Publiceringsår 2005
Publicerad vid Hjärt-kärlinstitutionen
Institutionen för laboratoriemedicin, Avdelningen för klinisk kemi/transfusionsmedicin
Sidor 433-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Coronary Angiography, Coronary Arteriosclerosis/*blood/etiology/radiography, Coronary Vessels/*pathology, Female, Follow-Up Studies, Gene Frequency, Genetic Markers, Graft Rejection/blood/prevention & control, Graft Survival/genetics, Heart Transplantation/*adverse effects/mortality, Humans, Immunosuppressive Agents/therapeutic use, Male, Middle Aged, Polymerase Chain Reaction, *Polymorphism, Genetic, Prospective Studies, Survival Rate, Transplantation, Homologous, Tumor Necrosis Factor-alpha/biosynthesis/*genetics
Ämneskategorier Kirurgi

Sammanfattning

BACKGROUND: Cardiac allograft vasculopathy (CAV) limits survival after cardiac transplantation. Tumor necrosis factor-alpha (TNF-alpha) may be a key factor in the development of CAV. Two bi-allelic polymorphisms associated with high TNF-alpha production have been identified in the TNF gene locus, TNFA1/2, at position -308 and TNFB1/2 at +252. We hypothesized that recipient TNFA2 and TNFB2 homozygosity is associated with the development of CAV after heart transplantation. METHODS: TNF gene polymorphisms were analyzed by multiplex fluorescent solid-phase mini-sequencing in 70 cardiac transplant recipients. Recipients homozygous for TNFA2 or TNFB2 (Group A, n = 29) were compared with recipients heterozygous or homozygous for TNFA1 and TNFB1 (Group B, n = 41). Coronary arteriography was performed annually or when indicated. Cumulative freedom from CAV and survival was calculated according to the Kaplan-Meier test. RESULTS: Mean follow-up was 3.8 +/- 0.3 years. In Group A, 11 of 29 recipients (38%) developed CAV compared with 9 of 41 (22%) in Group B (p = 0.12). Cumulative freedom from CAV at 3 years was 42% in Group A and 80% in Group B (p = 0.043). In Group A, 11 of 29 recipients (38%) died during follow-up compared with 4 of 41 (10%) in Group B (p = 0.006). Cumulative survival at 3 years was 72% in Group A and 93% in Group B (p = 0.003). CONCLUSIONS: The results suggest that TNFA2 and TNFB2 allele homozygosity is associated with cardiac allograft vasculopathy and mortality in heart transplant recipients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?